| 論文種別 | 原著論文 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. |
| 掲載誌名 | 正式名：Cancer medicine 略 称：Cancer Med ISSNコード：2045763420457634 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 6(11),pp.2646-2659 |
| 著者・共著者 | Yamaji M, Ota A, Wahiduzzaman Md, Karnan Sivasundaram, Hyodo T, Konishi H, Tsuzuki S, Hosokawa Y, Haniuda M |
| 発行年月 | 2017/11 |
| 概要 | Malignant pleural mesothelioma (MPM), an asbestos-related occupational disease, is an aggressive and incurable tumor of the thoracic cavity. Despite recent advances in MPM treatment, overall survival of patients with MPM is very low. Recent studies have implicated that PI3K/Akt signaling is involved in MPM cell survival and development. To investigate the effects of Akt inhibitors on MPM cell survival, we examined the effects of nine selective Akt inhibitors, namely, afuresertib, Akti-1/2, AZD5363, GSK690693, ipatasertib, MK-2206, perifosine,PHT-427, and TIC10, on six MPM cell lines, namely, ACC-MESO-4, Y-MESO-8A, MSTO-211H, NCI-H28, NCI-H290, and NCI-H2052, and a normal mesothelial cell line MeT-5A. Comparison of IC50 |
| NAID | 28960945 |